This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Jurcevic S, Klinga-Levan K, Olsson B, Ejeskär K. Verification of microRNA expression in human endometrial adenocarcinoma. BMC Cancer 2016; 16: 261. doi: 10.1186/s12885-016-2296-zJurcevicSKlinga-LevanKOlssonBEjeskärKVerification of microRNA expression in human endometrial adenocarcinoma20161626110.1186/s12885-016-2296-z547776127039384Open DOISearch in Google Scholar
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-86. doi: 10.1002/ijc.29210FerlayJSoerjomataramIDikshitREserSMathersCRebeloMet alCancer incidence and mortality worldwide: sources2015136E3598610.1002/ijc.2921025220842Open DOISearch in Google Scholar
Zhang H, Yan L, Bai Y, Li C, Guo Q, Wang C, et al. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia. Gynecol Oncol 2015; 136: 549-53. doi: 10.1016/j. ygyno.2014.11.008ZhangHYanLBaiYLiCGuoQWangCet alDual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia20151365495310.1016/j.ygyno.2014.11.00825451692Open DOISearch in Google Scholar
Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W, et al. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000; 7: 227-42.EmonsGFleckensteinGHinneyBHuschmandAHeylWet alHormonal interactions in endometrial cancer200072274210.1677/erc.0.007022711174845Search in Google Scholar
Cavanagh D, Fiorica JV, Hoffman MS, Durfee J, Nicosia SV. Adenocarcinoma of the endometrium: an Institutional review. Cancer Control 1999; 6: 354-60. doi: 10.1177/107327489900600405CavanaghDFioricaJVHoffmanMSDurfeeJNicosiaSVAdenocarcinoma of the endometrium: an Institutional review199963546010.1177/10732748990060040510758567Open DOISearch in Google Scholar
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005; 366: 491-505. doi: 10.1016/S0140-6736(05)67063-8AmantFMoermanPNevenPTimmermanDVanLimbergen EVergoteIEndometrial cancer200536649150510.1016/S0140-6736(05)67063-816084259Open DOISearch in Google Scholar
Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel) 1995; 154: 8-20.HayEDAn overview of epithelio-mesenchymal transformation199515482010.1159/0001477488714286Search in Google Scholar
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-90. doi: 10.1016/j. cell.2009.11.007ThieryJPAcloqueHHuangRYNietoMAEpithelial-mesenchymal transitions in development and disease20091398719010.1016/j.cell.2009.11.00719945376Open DOISearch in Google Scholar
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004; 10: 4125-33. doi: 10.1158/1078-0432.CCR-0578-03NakajimaSDoiRToyodaETsujiSWadaMKoizumiMet alN-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma20041041253310.1158/1078-0432.CCR-0578-0315217949Open DOISearch in Google Scholar
Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999; 18: 813-22. doi: 10.1038/ sj.onc.1202367HoshinoRChataniYYamoriTTsuruoTOkaHYoshidaOet alConstitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors1999188132210.1038/sj.onc.12023679989833Open DOISearch in Google Scholar
Zhang Z, Kobayashi S, Borczuk AC, Leidner RS, Laframboise T, Levine AD, et al., Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 2010; 31: 577-86. doi: 10.1093/carcin/bgq020ZhangZKobayashiSBorczukACLeidnerRSLaframboiseTLevineADet alDual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells2010315778610.1093/carcin/bgq020284709420097731Open DOISearch in Google Scholar
Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, et al. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 2008; 29: 1742-50. doi: 10.1093/carcin/bgn167ChanDWLiuVWTsaoGSYaoKMFurukawaTChanKKet alLoss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells20082917425010.1093/carcin/bgn16718632752Open DOISearch in Google Scholar
Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003; 162: 1807-15. doi: 10.1016/S0002-9440(10)64315-5FurukawaTSunamuraMMotoiFMatsunoSHoriiAPotential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer200316218071510.1016/S0002-9440(10)64315-5186813112759238Open DOISearch in Google Scholar
Patterson KI, Brummer T, O’Brien PM, Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 2009; 418: 475-89. doi: 10.1042/bj20082234PattersonKIBrummerTO’BrienPMDalyRJDual-specificity phosphatases: critical regulators with diverse cellular targets20094184758910.1042/bj2008223419228121Open DOISearch in Google Scholar
Arkell RS, Dickinson RJ, Squires M, Hayat S, Keyse SM, Cook SJ. DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5. Cell Signal 2008; 20: 836-43. doi: 10.1016/j.cellsig.2007.12.014ArkellRSDickinsonRJSquiresMHayatSKeyseSMCookSJDUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK52008208364310.1016/j.cellsig.2007.12.01418280112Open DOISearch in Google Scholar
Jurek A, Amagasaki K, Gembarska A, Heldin CH, Lennartsson J. Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. J Biol Chem 2009; 284: 4626-34. doi: 10.1074/ jbc.M808490200JurekAAmagasakiKGembarskaAHeldinCHLennartssonJNegative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation200928446263410.1074/jbc.M80849020019106095Open DOISearch in Google Scholar
Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010; 38: 114-27. doi: 10.1016/j.molcel.2010.02.020ShinSDimitriCAYoonSODowdleWBlenisJERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events2010381142710.1016/j.molcel.2010.02.020285467720385094Open DOISearch in Google Scholar
Chen HX, Xu XX, Tan BZ, Zhang Z, Zhou XD. MicroRNA-29b Inhibits angiogenesis by targeting VEGFA through the MAPK/ERK and PI3K/Akt signaling pathways in endometrial carcinoma. Cell Physiol Biochem 2017; 41: 933-46. doi: 10.1159/000460510ChenHXXuXXTanBZZhangZZhouXDMicroRNA-29b Inhibits angiogenesis by targeting VEGFA through the MAPK/ERK and PI3K/Akt signaling pathways in endometrial carcinoma2017419334610.1159/00046051028222438Open DOISearch in Google Scholar
Wang D, Wang D, Wang N, Long Z, Ren X. Long non-coding RNA BANCR promotes endometrial cancer cell proliferation and invasion by regulating MMP2 and MMP1 via ERK/MAPK signaling pathway. Cell Physiol Biochem 2016; 40: 644-56. doi: 10.1159/000452577WangDWangDWangNLongZRenXLong non-coding RNA BANCR promotes endometrial cancer cell proliferation and invasion by regulating MMP2 and MMP1 via ERK/MAPK signaling pathway2016406445610.1159/00045257727898420Open DOISearch in Google Scholar
Ma Z, Liu X, Li F, Wang Y, Xu Y, Zhang M, et al. Perfluorooctanoic acid induces human Ishikawa endometrial cancer cell migration and invasion through activation of ERK/mTOR signaling. Oncotarget 2016; 7: 66558-68. doi: 10.18632/oncotarget.11684MaZLiuXLiFWangYXuYZhangMet alPerfluorooctanoic acid induces human Ishikawa endometrial cancer cell migration and invasion through activation of ERK/mTOR signaling20167665586810.18632/oncotarget.11684534182027589685Open DOISearch in Google Scholar
Wong VC, Chen H, Ko JM, Chan KW, Chan YP, Law S, et al. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer 2012; 130: 83-95. doi: 10.1002/ijc.25970WongVCChenHKoJMChanKWChanYPLawSet alTumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype2012130839510.1002/ijc.2597021387288Open DOISearch in Google Scholar
Wu QN, Liao YF, Lu YX, Wang Y, Lu JH, Zeng ZL, et al. Pharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance. Cancer Lett 2018; 412: 243-55. doi: 10.1016/j. canlet.2017.10.007WuQNLiaoYFLuYXWangYLuJHZengZLet alPharmacological inhibition of DUSP6 suppresses gastric cancer growth and metastasis and overcomes cisplatin resistance20184122435510.1016/j.canlet.2017.10.00729050982Open DOISearch in Google Scholar
Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-58. doi: 10.1016/j.ceb.2005.08.001HuberMAKrautNBeugHMolecular requirements for epithelial-mesenchymal transition during tumor progression2005175485810.1016/j.ceb.2005.08.00116098727Open DOISearch in Google Scholar
McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr 2016; 7: 418-9. doi: 10.3945/an.116.012211.McGuireS2014Geneva, SwitzerlandWorld Health Organization, International Agency for Research on Cancer, WHO Press2015. Adv Nutr 20167418910.3945/an.116.012211478548526980827Open DOISearch in Google Scholar
Zhang H, Guo Q, Wang C, Yan L, Fu Y, Fan M, et al. Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estrodial-induced cell growth in endometrial adenocarcinoma cell. Mol Cell Endocrinol 2013; 376: 60-9. doi: 10.1016/j.mce.2013.02.007ZhangHGuoQWangCYanLFuYFanMet alDual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estrodial-induced cell growth in endometrial adenocarcinoma cell201337660910.1016/j.mce.2013.02.00723419500Open DOISearch in Google Scholar
Mayama T, Fukushige S, Shineha R, Nishihira T, Satomi S, Horii A, et al. Frequent loss of copy number on the long arm of chromosome 21 in human esophageal squamous cell carcinoma. Int J Oncol 2000; 17: 245-52.MayamaTFukushigeSShinehaRNishihiraTSatomiSHoriiAet alFrequent loss of copy number on the long arm of chromosome 21 in human esophageal squamous cell carcinoma2000172455210.3892/ijo.17.2.245Search in Google Scholar
Lo KW, Teo PM, Hui AB, To KF, Tsang YS, Chan SY, et al. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res 2000; 60: 3348-53. doi: 10.3892/ijo.17.2.245LoKWTeoPMHuiABToKFTsangYSChanSYet alHigh resolution allelotype of microdissected primary nasopharyngeal carcinoma20006033485310.3892/ijo.17.2.245Open DOISearch in Google Scholar
Shaw KR, Wrobel CN, Brugge JS. Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 2004; 9: 297-310. doi: 10.1007/s10911-004-1402-zShawKRWrobelCNBruggeJSUse of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis2004929731010.1007/s10911-004-1402-z150910215838601Open DOISearch in Google Scholar
Liu LK, Jiang XY, Zhou XX, Wang DM, Song XL, Jiang HB, et al. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod Pathol 2010; 23: 213-24. doi: 10.1038/ modpathol.2009LiuLKJiangXYZhouXXWangDMSongXLJiangHBet alUpregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome2010232132410.1038/modpathol.2009Open DOISearch in Google Scholar
Camps M, Nichols A, Gillieron C, Antonsson B, Muda M, Chabert C, et al. Catalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase. Science 1998; 280: 1262-5. doi: 10.1126/sci-ence.280.5367.1262CampsMNicholsAGillieronCAntonssonBMudaMChabertCet alCatalytic activation of the phosphatase MKP-3 by ERK2 mitogen-activated protein kinase19982801262510.1126/sci-ence.280.5367.1262Open DOISearch in Google Scholar